Ratings Xbrane Biopharma AB

Equities

XBRANE

SE0007789409

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.234 ^SEK	+5.88%		-13.33%	-97.66%

May. 22	Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?	CI
May. 16	Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XBRANE BIOPHARMA AB	-97.66%	33.98M	C+
MODERNA, INC.	+22.10%	46.55B	B-
LONZA GROUP AG	+46.45%	41.84B	A
IQVIA HOLDINGS INC.	-3.12%	40.84B	B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B	B
CELLTRION, INC.	-6.30%	28.27B	C
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B	B-
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B	B+
MEDPACE HOLDINGS, INC.	+44.52%	13.69B	C+
BIO-TECHNE CORPORATION	+0.19%	12.18B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes